EUVIMEDEUVIMED entdecken
Crossref

Outcomes and dosimetric analysis of reirradiation of oral cavity and oropharyngeal cancers with high-dose-rate brachytherapy

Christina Phuong, Lisa Ni, Manju Sharma, J Adam M Cunha, Sue S Yom, I-Chow Hsu, Jason W Chan

Brachytherapy · 2025

DOI: 10.1016/j.brachy.2025.02.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brachytherapy, 2025. Verfasst von Christina Phuong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of California San Francisco, San Francisco, CA. Hauptthemen laut MEDLINE: Brachytherapy, Oropharyngeal Neoplasms, Re-Irradiation, Mouth Neoplasms. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This study sought to evaluate the outcomes and toxicities from oral cavity (OC) and oropharynx (OP) high-dose-rate brachytherapy (HDRBT) for re-irradiation (reRT) of head and neck squamous cell carcinoma (HNSCC). METHODS: Patients who previously received curative-intent external beam radiotherapy for primary HNSCC and were treated with OC/OP reRT with HDRBT from January 2000 to December 2021 were included. Patients were selected by a multidisciplinary tumor board to be appropriate candidates for HDRBT for one of two reRT indications: (1) definitive reRT or (2) postoperative reRT. Survival outcomes were estimated using the Kaplan-Meier method. Efficacy and toxicity outcomes were analyzed for the entire cohort and separately based on reRT indication. RESULTS: 27 patients were evaluated with a median follow up of 20 (IQR 12-41) mo. 14 (52%) and 13 (48%) patients were treated for a recurrent or second primary OC and OP HNSCC, respectively. Median dose of prior EBRT was 68.4 (IQR 60-70) Gy. Median interval between completion of EBRT to HDRBT reRT was 42 (IQR 14-85) mo. Median target volume was 16 (IQR 10-29) cc; median D90% was 31 (IQR 30-36) Gy. In cohorts A and B, 2-year LC/late grade ≥3 toxicity were 70%/57% and 60%/15%, respectively. CONCLUSIONS: HDRBT for reRT of small (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BrachytherapyOropharyngeal NeoplasmsRe-IrradiationMouth NeoplasmsSquamous Cell Carcinoma of Head and NeckHumansMaleFemaleMiddle AgedRadiotherapy DosageAgedTreatment OutcomeRetrospective Studies

Stichwörter der Autor:innen

HDR brachytherapyHead and neckIPSAInverse planning simulated annealingRecurrenceReirradiation

Autor:innen und Institutionen

  • Department of Radiation Oncology, University of California San Francisco, San Francisco, CA.
  • Department of Radiation Oncology, University of California San Francisco, San Francisco, CA. Electronic address: Jason.w.chan@ucsf.edu.

Zitieren

APA

Phuong, C., Ni, L., Sharma, M., Cunha, J. A. M., Yom, S. S., Hsu, I. C., & Chan, J. W. (2025). Outcomes and dosimetric analysis of reirradiation of oral cavity and oropharyngeal cancers with high-dose-rate brachytherapy. Brachytherapy. https://doi.org/10.1016/j.brachy.2025.02.002

Vancouver

Phuong C, Ni L, Sharma M, Cunha JAM, Yom SS, Hsu IC, et al. Outcomes and dosimetric analysis of reirradiation of oral cavity and oropharyngeal cancers with high-dose-rate brachytherapy. Brachytherapy. 2025. doi:10.1016/j.brachy.2025.02.002

BibTeX
@article{Phuong2025,
  author = {Phuong, Christina and Ni, Lisa and Sharma, Manju and Cunha, J Adam M and Yom, Sue S and Hsu, I-Chow and Chan, Jason W},
  title = {Outcomes and dosimetric analysis of reirradiation of oral cavity and oropharyngeal cancers with high-dose-rate brachytherapy},
  journal = {Brachytherapy},
  year = {2025},
  doi = {10.1016/j.brachy.2025.02.002}
}
Kostenlos starten →